Literature DB >> 34308831

Complementary Medicine in the Treatment of Cancer Patients.

Jutta Hübner1, Matthias Beckmann, Markus Follmann, Monika Nothacker, Franz Josef Prott, Bernhard Wörmann.   

Abstract

BACKGROUND: Approximately half of all patients with cancer use at least one method of complementary medicine during or after tumor treatment. The substances most commonly taken are micronutrients, food supplements, and plant extracts.
METHODS: This guideline is based on pertinent articles retrieved by a systematic search in the Medline, Cochrane Library, Embase, PsycInfo, and Cinahl databases.
RESULTS: The evidence is offen scant for any effect of a complementary method on patient-relevant endpoints such as relief of disease symptoms, reduction of treatment side effects, or prolonged survival. Micronutrients are available in different compositions, and their dosages vary. In most studies on the use of vitamins and trace elements by cancer patients, the blood level of the substance in question was not measured before its administration, so that it remains unknown whether a deficiency was present. For this reason, no well-founded conclusion on the effects of these substances can be drawn, and their use cannot be recommended in most cases. On the other hand, there is high-level evidence supporting physical exercise by cancer patients during and after their treatment. For patients with any type of cancer, mortality is lower among those who perform more physical exercise, whether before or after they receive the diagnosis of cancer (exercise before diagnosis, hazard ratio [HR] 0.82, 95% confidence interval [CI] [0.79; 0.86]; exercise after diagnosis, HR 0.63, 95% CI [0.53; 0.75]). Physical exercise during and after treatment for cancer should, therefore, be recommended to all cancer patients.
CONCLUSION: The inherent positive attribute of complementary medicine is patient empowerment: it enables patients to help themselves in an active way even while undergoing cancer treatment, as well as afterward. To avoid risks to health, patients should be instructed about unsafe methods, asked repeatedly about their use of complementary medicine, and informed specifically about potential interactions between such interventions and their cancer treatment.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 34308831      PMCID: PMC8762594          DOI: 10.3238/arztebl.m2021.0277

Source DB:  PubMed          Journal:  Dtsch Arztebl Int        ISSN: 1866-0452            Impact factor:   8.251


  40 in total

1.  Randomized trial of vitamin D3 to prevent worsening of musculoskeletal symptoms in women with breast cancer receiving adjuvant letrozole. The VITAL trial.

Authors:  Qamar J Khan; Bruce F Kimler; Pavan S Reddy; Priyanka Sharma; Jennifer R Klemp; Jennifer L Nydegger; Hung-Wen Yeh; Carol J Fabian
Journal:  Breast Cancer Res Treat       Date:  2017-08-02       Impact factor: 4.872

2.  Antioxidant vitamins supplementation and mortality: a randomized trial in head and neck cancer patients.

Authors:  Isabelle Bairati; François Meyer; Edith Jobin; Michel Gélinas; André Fortin; Abdenour Nabid; François Brochet; Bernard Têtu
Journal:  Int J Cancer       Date:  2006-11-01       Impact factor: 7.396

3.  Mistletoe in oncological treatment: a systematic review : Part 2: quality of life and toxicity of cancer treatment.

Authors:  M Freuding; C Keinki; S Kutschan; O Micke; J Buentzel; Jutta Huebner
Journal:  J Cancer Res Clin Oncol       Date:  2019-01-23       Impact factor: 4.553

4.  Limited effects of selenium substitution in the prevention of radiation-associated toxicities. results of a randomized study in head and neck cancer patients.

Authors:  J Büntzel; D Riesenbeck; M Glatzel; R Berndt-Skorka; T Riedel; R Mücke; K Kisters; K G Schönekaes; U Schäfer; F Bruns; O Micke
Journal:  Anticancer Res       Date:  2010-05       Impact factor: 2.480

5.  A phase II randomized double-blind placebo-controlled study of 6-gingerol as an anti-emetic in solid tumor patients receiving moderately to highly emetogenic chemotherapy.

Authors:  J Konmun; K Danwilai; N Ngamphaiboon; B Sripanidkulchai; A Sookprasert; S Subongkot
Journal:  Med Oncol       Date:  2017-03-27       Impact factor: 3.064

6.  Randomized, open-label phase III trial of docetaxel plus high-dose calcitriol versus docetaxel plus prednisone for patients with castration-resistant prostate cancer.

Authors:  Howard I Scher; Xiaoyu Jia; Kim Chi; Ronald de Wit; William R Berry; Peter Albers; Brian Henick; David Waterhouse; Dean J Ruether; Peter J Rosen; Anthony A Meluch; Luke T Nordquist; Peter M Venner; Axel Heidenreich; Luis Chu; Glenn Heller
Journal:  J Clin Oncol       Date:  2011-04-11       Impact factor: 44.544

Review 7.  Is there a role for oral or intravenous ascorbate (vitamin C) in treating patients with cancer? A systematic review.

Authors:  Carmel Jacobs; Brian Hutton; Terry Ng; Risa Shorr; Mark Clemons
Journal:  Oncologist       Date:  2015-01-19

8.  Protective effect of alpha-tocopherol in head and neck cancer radiation-induced mucositis: a double-blind randomized trial.

Authors:  Paulo Renato Ferreira; James Freitas Fleck; Ada Diehl; Daniela Barletta; Aroldo Braga-Filho; Antonio Barletta; Ligia Ilha
Journal:  Head Neck       Date:  2004-04       Impact factor: 3.147

Review 9.  Exercise for Men with Prostate Cancer: A Systematic Review and Meta-analysis.

Authors:  Liam Bourke; Dianna Smith; Liz Steed; Richard Hooper; Anouska Carter; James Catto; Peter C Albertsen; Bertrand Tombal; Heather A Payne; Derek J Rosario
Journal:  Eur Urol       Date:  2015-11-26       Impact factor: 20.096

10.  Impact of treatment planning target volumen (PTV) size on radiation induced diarrhoea following selenium supplementation in gynecologic radiation oncology--a subgroup analysis of a multicenter, phase III trial.

Authors:  Ralph Muecke; Oliver Micke; Lutz Schomburg; Jens Buentzel; Michael Glatzel; Dieter Baaske; Regina Berndt-Skorka; Franz J Prott; Berthold Reichl; Klaus Kisters; Ulrich Schaefer; Jutta Huebner; Hans Th Eich; Guenther Kundt; Irenaeus A Adamietz
Journal:  Radiat Oncol       Date:  2013-03-25       Impact factor: 3.481

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.